BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Haastrup PF, Thompson W, Søndergaard J, Jarbøl DE. Side Effects of Long-Term Proton Pump Inhibitor Use: A Review. Basic Clin Pharmacol Toxicol 2018;123:114-21. [PMID: 29658189 DOI: 10.1111/bcpt.13023] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Herbella FAM, Patti MG. Gastroesophageal Reflux Disease and Idiopathic Lung Fibrosis. From Heartburn to Lung Transplant, and Beyond. Am Surg 2021;:3134821998686. [PMID: 33629881 DOI: 10.1177/0003134821998686] [Reference Citation Analysis]
2 Hendricks E, Ajmeri AN, Singh MM, Mongalo M, Goebel LJ. A Randomized Open-Label Study of Two Methods of Proton Pump Inhibitors Discontinuation. Cureus 2021;13:e15022. [PMID: 34150379 DOI: 10.7759/cureus.15022] [Reference Citation Analysis]
3 da Mata AMOF, Paz MFCJ, de Menezes APM, Dos Reis AC, da Silva Souza B, de Carvalho Sousa CD, Machado SA, Medeiros TSG, Sarkar C, Islam MT, Sharifi-Rad J, Daştan SD, Alshehri MM, de Castro E Sousa JM, de Carvalho Melo Cavalcante AA. Evaluation of mutagenesis, necrosis and apoptosis induced by omeprazole in stomach cells of patients with gastritis. Cancer Cell Int 2022;22:154. [PMID: 35436881 DOI: 10.1186/s12935-022-02563-5] [Reference Citation Analysis]
4 Haastrup PF, Jarbøl DE, Thompson W, Hansen JM, Søndergaard J, Rasmussen S. When does proton pump inhibitor treatment become long term? A scoping review. BMJ Open Gastroenterol 2021;8:e000563. [PMID: 33589415 DOI: 10.1136/bmjgast-2020-000563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Saiz Ladera GM, Pejenaute Labari ME, García Pascual JN. [Updating in prescription of proton pump inhibitors. What to do and what not to do]. Semergen 2021;47:267-79. [PMID: 33223372 DOI: 10.1016/j.semerg.2020.09.011] [Reference Citation Analysis]
6 Fatima K, Almas T, Lakhani S, Jahangir A, Ahmed A, Siddiqui A, Rahim A, Qureshi SA, Arshad Z, Golani S, Musheer A. The Use of Proton Pump Inhibitors and COVID-19: A Systematic Review and Meta-Analysis. TropicalMed 2022;7:37. [DOI: 10.3390/tropicalmed7030037] [Reference Citation Analysis]
7 Sykes BW. A free ride: Is long‐term omeprazole therapy safe and effective? Equine Vet Educ 2021;33:556-60. [DOI: 10.1111/eve.13458] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Daliri S, Bouhnouf M, van de Meerendonk HW, Buurman BM, Scholte op Reimer WJ, Kooij MJ, Karapinar – Çarkit F. Longitudinal medication reconciliation at hospital admission, discharge and post-discharge. Research in Social and Administrative Pharmacy 2021;17:677-84. [DOI: 10.1016/j.sapharm.2020.05.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Marks SL, Kook PH, Papich MG, Tolbert MK, Willard MD. ACVIM consensus statement: Support for rational administration of gastrointestinal protectants to dogs and cats. J Vet Intern Med 2018;32:1823-40. [PMID: 30378711 DOI: 10.1111/jvim.15337] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 6.8] [Reference Citation Analysis]
10 Tuppin P, Rivière S, Deutsch D, Gastaldi-Menager C, Sabaté JM. Burden of drug use for gastrointestinal symptoms and functional gastrointestinal disorders in France: a national study using reimbursement data for 57 million inhabitants. Therap Adv Gastroenterol 2019;12:1756284819853790. [PMID: 31320929 DOI: 10.1177/1756284819853790] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Governa P, Biagi M. Copaifera langsdorffii Desf.: in vitro investigation on anti- Helicobacter pylori and anti-inflammatory activities of oleoresin and fruit methanolic extract. Plant Biosystems - An International Journal Dealing with all Aspects of Plant Biology 2020;154:117-24. [DOI: 10.1080/11263504.2019.1578284] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
12 Konstantinidou SK, Kostaras P, Anagnostopoulos GE, Markantonis SL, Karalis V, Konstantinidis K. A retrospective study on the evaluation of the symptoms, medications and improvement of the quality of life of patients undergoing robotic surgery for gastroesophageal reflux disease. Exp Ther Med 2021;21:174. [PMID: 33456541 DOI: 10.3892/etm.2020.9605] [Reference Citation Analysis]
13 Vatcharavongvan P, Puttawanchai V. Elderly Patients in Primary Care are Still at Risks of Receiving Potentially Inappropriate Medications. J Prim Care Community Health 2021;12:21501327211035088. [PMID: 34315288 DOI: 10.1177/21501327211035088] [Reference Citation Analysis]
14 Franchi C, Mannucci PM, Nobili A, Ardoino I. Use and prescription appropriateness of drugs for peptic ulcer and gastrooesophageal reflux disease in hospitalized older people. Eur J Clin Pharmacol 2020;76:459-65. [PMID: 31853593 DOI: 10.1007/s00228-019-02815-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
15 Sverdén E, Agréus L, Dunn JM, Lagergren J. Peptic ulcer disease. BMJ 2019;367:l5495. [PMID: 31578179 DOI: 10.1136/bmj.l5495] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
16 Fan X, Yang XS, Bai P, Ren YB, Zhang L, Li X, Wang L, Wang Y, Ding YM, Zeng RR, Lin XC. Gastric adenocarcinoma of the fundic gland type: A case report. Medicine (Baltimore) 2020;99:e20361. [PMID: 32481329 DOI: 10.1097/MD.0000000000020361] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Nguyen-Soenen J, Jourdain M, Fournier JP. Development of Patient Education Material for Proton Pump Inhibitor Deprescribing: A Mixed-Methods Study. Ann Pharmacother 2021;:10600280211046630. [PMID: 34553640 DOI: 10.1177/10600280211046630] [Reference Citation Analysis]
18 Öztekin M, Yılmaz B, Ağagündüz D, Capasso R. Overview of Helicobacter pylori Infection: Clinical Features, Treatment, and Nutritional Aspects. Diseases 2021;9:66. [PMID: 34698140 DOI: 10.3390/diseases9040066] [Reference Citation Analysis]
19 Fuentes-Valenzuela E, Díez Redondo P, Tejedor-Tejada J, Nájera-Muñoz R, Sánchez-Delgado L, Maroto-Martín C. [Proton-pump inhibitors treatment. Does your patient really need it?]. Semergen 2021:S1138-3593(21)00266-5. [PMID: 34728148 DOI: 10.1016/j.semerg.2021.08.002] [Reference Citation Analysis]
20 Brusselaers N, Lagergren J, Engstrand L. Duration of use of proton pump inhibitors and the risk of gastric and oesophageal cancer. Cancer Epidemiol 2019;62:101585. [PMID: 31445426 DOI: 10.1016/j.canep.2019.101585] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
21 Singh-Franco D, Mastropietro DR, Metzner M, Dressler MD, Fares A, Johnson M, De La Rosa D, Wolowich WR. Impact of pharmacy-supported interventions on proportion of patients receiving non-indicated acid suppressive therapy upon discharge: A systematic review and meta-analysis. PLoS One 2020;15:e0243134. [PMID: 33270710 DOI: 10.1371/journal.pone.0243134] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Lee L, Ramos-Alvarez I, Ito T, Jensen RT. Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger-Ellison Syndrome. Int J Mol Sci 2019;20:E5128. [PMID: 31623145 DOI: 10.3390/ijms20205128] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
23 Demcsák A, Soós A, Kincses L, Capunge I, Minkov G, Kovacheva-Slavova M, Nakov R, Wu D, Huang W, Xia Q, Deng L, Hollenbach M, Schneider A, Hirth M, Ioannidis O, Vincze Á, Bajor J, Sarlós P, Czakó L, Illés D, Izbéki F, Gajdán L, Papp M, Hamvas J, Varga M, Kanizsai P, Bóna E, Mikó A, Váncsa S, Juhász MF, Ocskay K, Darvasi E, Miklós E, Erőss B, Szentesi A, Párniczky A, Casadei R, Ricci C, Ingaldi C, Mastrangelo L, Jovine E, Cennamo V, Marino MV, Barauskas G, Ignatavicius P, Pelaez-Luna M, Rios AS, Turcan S, Tcaciuc E, Małecka-Panas E, Zatorski H, Nunes V, Gomes A, Gonçalves TC, Freitas M, Constantino J, Sá M, Pereira J, Mateescu B, Constantinescu G, Sandru V, Negoi I, Ciubotaru C, Negoita V, Bunduc S, Gheorghe C, Barbu S, Tantau A, Tantau M, Dumitru E, Suceveanu AI, Tocia C, Gherbon A, Litvin A, Shirinskaya N, Rabotyagova Y, Bezmarevic M, Hegyi PJ, Han J, Rodriguez-Oballe JA, Salas IM, Comas EP, Garcia DI, Cuadrado AJ, Castiñeira AQ, Chang YT, Chang MC, Kchaou A, Tlili A, Kacar S, Gökbulut V, Duman D, Kani HT, Altintas E, Chooklin S, Chuklin S, Gougol A, Papachristou G, Hegyi P. Acid suppression therapy, gastrointestinal bleeding and infection in acute pancreatitis - An international cohort study. Pancreatology 2020;20:1323-31. [PMID: 32948430 DOI: 10.1016/j.pan.2020.08.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
24 Molavipordanjani S, Abedi SM, Hosseinimehr SJ, Fatahian A, Mardanshahi A. The effects of pharmacological interventions, exercise, and dietary supplements on extra-cardiac radioactivity in myocardial perfusion single-photon emission computed tomography imaging. Nucl Med Commun 2020;41:841-7. [PMID: 32796471 DOI: 10.1097/MNM.0000000000001226] [Reference Citation Analysis]
25 Wehmeyer MH, Horvatits T, Buchholz A, Krause L, Walter S, Zapf A, Lohse AW, Kluwe J; STOPPIT-trial group. Stop of proton-pump inhibitor treatment in patients with liver cirrhosis (STOPPIT): study protocol for a prospective, multicentre, controlled, randomized, double-blind trial. Trials 2022;23:302. [PMID: 35414106 DOI: 10.1186/s13063-022-06232-w] [Reference Citation Analysis]
26 Renzi A, Di Sarno G, d'Aniello F, Brillantino A, Minieri G, Coretti G, Barbato D, Barone G. Complete Fundus Mobilization Reduces Dysphagia After Nissen Procedure. Surg Innov 2021;28:272-83. [PMID: 33236675 DOI: 10.1177/1553350620971174] [Reference Citation Analysis]
27 Wu B, Li D, Xu T, Luo M, He Z, Li Y. Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system. Sci Rep 2021;11:3690. [PMID: 33574396 DOI: 10.1038/s41598-021-83099-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
28 Liu L, Yu Y, Fan Q, Wu Z, Li X, Luo H. Impact of proton pump inhibitor management committee's multifaceted interventions on acid suppressant prescribing patterns in outpatient and emergency departments. BMC Health Serv Res 2022;22:417. [PMID: 35351121 DOI: 10.1186/s12913-022-07820-x] [Reference Citation Analysis]
29 Yibirin M, De Oliveira D, Valera R, Plitt AE, Lutgen S. Adverse Effects Associated with Proton Pump Inhibitor Use. Cureus 2021;13:e12759. [PMID: 33614352 DOI: 10.7759/cureus.12759] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
30 Deng S, Sun Y, Zhao T, Hu Y, Zang T. A Review of Drug Side Effect Identification Methods. Curr Pharm Des 2020;26:3096-104. [PMID: 32532187 DOI: 10.2174/1381612826666200612163819] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Bosnjak T, Solberg R, Hemati PD, Jafari A, Kassem M, Johansen HT. Lansoprazole inhibits the cysteine protease legumain by binding to the active site. Basic Clin Pharmacol Toxicol 2019;125:89-99. [PMID: 30916878 DOI: 10.1111/bcpt.13230] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
32 Wu B, Hu Q, Tian F, Wu F, Li Y, Xu T. A pharmacovigilance study of association between proton pump inhibitor and dementia event based on FDA adverse event reporting system data. Sci Rep 2021;11:10709. [PMID: 34021217 DOI: 10.1038/s41598-021-90108-7] [Reference Citation Analysis]
33 Matuz M, Benkő R, Engi Z, Schváb K, Doró P, Viola R, Szabó M, Soós G. Use of Proton Pump Inhibitors in Hungary: Mixed-Method Study to Reveal Scale and Characteristics. Front Pharmacol 2020;11:552102. [PMID: 33013389 DOI: 10.3389/fphar.2020.552102] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
34 Sasaki T, Mori S, Kishi S, Fujiwara-Tani R, Ohmori H, Nishiguchi Y, Hojo Y, Kawahara I, Nakashima C, Fujii K, Luo Y, Kuniyasu H. Effect of Proton Pump Inhibitors on Colorectal Cancer. Int J Mol Sci 2020;21:E3877. [PMID: 32485921 DOI: 10.3390/ijms21113877] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
35 Tanus-Santos JE, Pinheiro LC. Proton pump inhibitors: New mechanisms of action. Basic Clin Pharmacol Toxicol 2019;125:87-8. [PMID: 30980783 DOI: 10.1111/bcpt.13237] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
36 Siboni S, Sozzi M, Capuzzo M, Buogo A, Riva CG, Ferrari D, Bonavina L. Combined pharmacologic antireflux therapy after esophagectomy: effect on symptoms and endoscopic findings at 1-year follow-up. Eur Surg 2020;52:118-22. [DOI: 10.1007/s10353-020-00635-2] [Reference Citation Analysis]
37 Çelik F, Aypak C, Özdemir A, Görpelioğlu S. Inappropriate Prescribing of Proton Pump Inhibitors in Outpatient Clinics. Gastroenterol Nurs 2021;44:84-91. [PMID: 33795619 DOI: 10.1097/SGA.0000000000000500] [Reference Citation Analysis]
38 Sendzischew Shane MA, Moshiree B. Esophageal and Gastric Motility Disorders in the Elderly. Clin Geriatr Med 2021;37:1-16. [PMID: 33213764 DOI: 10.1016/j.cger.2020.08.002] [Reference Citation Analysis]
39 Thompson W, Nissen M, Haastrup P, Le JV, Lundby C, Nielsen JB, Jarbøl DE. Discussing proton pump inhibitor deprescribing: the views of Danish GPs and older patients. BMC Fam Pract 2020;21:160. [PMID: 32770959 DOI: 10.1186/s12875-020-01227-5] [Reference Citation Analysis]
40 Sarnaik MK, Modi S, Pisipati Y, Vaidya S, Syed Gaggatur N, Sange AH, Srinivas N, Sange I. Proton Pump Inhibitors: Exploring Cardiovascular Complications and Prescription Protocol. Cureus 2021;13:e16744. [PMID: 34354892 DOI: 10.7759/cureus.16744] [Reference Citation Analysis]